Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK

British Journal of Cancer

Volumn 102, Issue 5, 2010, Pages 933-939

  Cuzick, J ^a   Castaon A ^a   Sasieni, P ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cervical cancer; Cervical screening; CIN; Cytology; HPV vaccination; Modelling

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; AGED; ARTICLE; CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER SCREENING; CHILD; FEMALE; GROUPS BY AGE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INVASIVE CARCINOMA; PRIORITY JOURNAL; SCHOOL CHILD; UNITED KINGDOM; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DISEASE;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; FEMALE; GREAT BRITAIN; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; INCIDENCE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRECANCEROUS CONDITIONS; PROGNOSIS; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 77649271813     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605528     Document Type: Article

References (37)

1. Brotherton JM, Deeks SL, Campbell-Lloyd S, Misrachi A, Passaris I, Peterson K, Pitcher H, Scully M, Watson M, Webby R (2008) Interim estimates of human papillomavirus vaccination coverage in the school-based program in Australia. Commun Dis Intel 32(4): 457-461
2. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, Sings HL, James M, Hesley TM, Barr E (2009) The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 199(7): 926-935
3. Bruni L, Ferrer E, Diaz M, Louie KS, Albero G, Muñoz J, Castellsagué X, Bosch F, de Sanjosé S (2009) Worldwide HPV type-specific prevalence in cytologically normal women (1995-2008). Abstract O-30.05. 25th International Papilloma Virus Conference. Malmo, Sweden
4. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, Voorhorst FJ, Verheijen RH, van Groningen K, Boon ME, Ruitinga W, van Ballegooijen M, Snijders PJ, Meijer CJ (2007) Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 370(9601): 1764-1772
5. Clifford G, Franceschi S, Diaz M, Muñoz N, Villa LL (2006) Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 24(Suppl 3): S3/26-34
6. Cuzick J, Szarewski A, Mesher D, Cadman L, Austin J, Perryman K, Ho L, Terry G, Sasieni P, Dina R, Soutter WP (2008) Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology-results from the Hammersmith study. Int J Cancer 122(10): 2294-2300
7. De Carvalh N, Roteli-Martin CM, Teixeira J, Naud P, de Borba P, Zahaf T, Sanchez N, Schuind A (2009) Immunogenicity and safety of HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years. Abstract presented at the 25th IPV conference. 8-14
8. May 2009; Malmo, Sweden de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, Bosch FX (2007) Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 7(7) 453-459.
9. Department of Health (2003) Cervical Screening Programme, England: 2002-2003 Department of Health, Statistical bulletins: London
10. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, de Sanjose S, Naucler P, Lloveras B, Kjaer S, Cuzick J, van Ballegooijen M, Clavel C, Iftner T, Joint European Cohort Study (2008) Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: Joint European Cohort Study. BMJ 337: a1754
11. Dobson S, Dawar M, Scheifele D, Kollmann T, McNeil S, Halperin S, Langley J, Dionne M, Picard M-E, Sauvageau C, Krajden M, Marra F, Miller D, Money D, Naus M, Ogilvie G, Singer J, Bettinger J, Young E (2009) Are 2 doses of HPV vaccine adequate in girls?. Abstract presented at the 25th IPV conference, 8-14
12. May 2009; Malmo, Sweden Franceschi S, Clifford GM (2008) Fraction of cervical neoplasias due to human papillomavirus 16 and 18 in vaccine trials. Int J Cancer 122(3): 719-720
13. FUTURE II Study Group (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356(19): 1915-1927
14. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA, Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356(19): 1928-1943
15. Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ (2008) Cost-effectiveness of cervical cancer screening with human papilloma-virus DNA testing and HPV-16, 18 vaccination. J Natl Cancer Inst 100(5): 308-320
16. Guttmacher Institute (2006) Facts on American teens' sexual and reproductive health Retrieved April 2009, from http://www.guttmacher. org/pubs/fb-ATSRH.pdf
17. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G, GlaxoSmithKline HPV Vaccine Study Group (2004) Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364(9447): 1757-1765
18. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G, HPV Vaccine Study group (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367(9518): 1247-1255
19. Hibbitts S, Jones J, Powell N, Dallimore N, McRea J, Beer H, Tristram A, Fielder H, Fiander AN (2008) Human papillomavirus prevalence in women attending routine cervical screening in South Wales, UK: a cross-sectional study. Br J Cancer 99(11): 1929-1933
20. Information Services Division NHS National Services Scotland (2009) Childhood immunisations. Provisional human papilloma virus (HPV) immunisation uptake rates: as at 16 February 2009. Retrieved 16 April 2009 from http://www.isdscotland.org/isd/5921.html
21. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, Alvarez FB, Bautista OM, Jansen KU, Barr E (2006) Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 107(1): 18-27
22. Moscicki AB, Hills N, Shiboski S, Powell K, Jay N, Hanson E, Miller S, Clayton L, Farhat S, Broering J, Darragh T, Palefsky J (2001) Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 285(23): 2995-3002
23. NHS Immunisation Information (2009) HPV vaccine uptake April 2009-provisional data. Retrieved August 2009 from http://www. immunisation.nhs.uk/Library/News/hpv-uptake-april09
24. Office for National Statistics (1999) Cancer 1971-1997 (CD Rom). ONS: London Office for National Statistics (2003) Cancer Statistics Registrations Series MB1 no.34 ONS
25. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, Greenacre M, HPV PATRICIA Study Group (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374(9686): 301-314
26. Sargent A, Bailey A, Almonte M, Turner A, Thomson C, Peto J, Desai M, Mather J, Moss S, Roberts C, Kitchener HC, ARTISTIC Study Group (2008) Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial. Br J Cancer 98(10): 1704-1709
27. Sasieni P, Castanon A, Parkin DM (2009) How many cervical cancers are prevented by treatment of screen-detected disease in young women? Int J Cancer 124(2): 461-464
28. Schiller JT, Castellsagué X, Villa LL, Hildesheim A (2008) An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 26(Suppl 10): K53-K61
29. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM (2007) Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121(3): 621-632
30. Trottier H, Mahmud SM, Lindsay L, Jenkins D,Quint W,Wieting SL, Schuind A,Franco EL, GSK HPV-001
31. Trottier H, Mahmud SM, Lindsay L, Jenkins D, Quint W, Wieting SL, Schuind A, Franco EL, GSK HPV-001
32. Vaccine Study Group (2009) Persistence of an incident human papillomavirus infection and timing of cervical lesions in previously unexposed young women. Cancer Epidemiol Biomarkers Prev 18(3): 854-862
33. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Høye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, Krogh G, Lehtinen M, Malm C, Tamms GM, Giacoletti K, Lupinacci L, Railkar R, Taddeo FJ, Bryan J, Esser MT, Sings HL, Saah AJ, Barr E (2006) High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95(11): 1459-1466
34. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189(1): 12-19
35. Wellings K, Nanchahal K, Macdowall W, McManus S, Erens B, Mercer CH, Johnson AM, Copas AJ, Korovessis C, Fenton KA, Field J (2001) Sexual behaviour in Britain: early heterosexual experience. Lancet 358(9296): 1843-1850
36. Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, Garćia P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, James M, Vuocolo S, Hesley TM, Barr E (2009) The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 199(7): 936-944
37. WHO/ICO Information Centre on Human Papilloma Virus (HPV) and Cervical Cancer (2007) Burden of HPV related cancers. Retrieved 17 April 2009, from http://www.who.int/hpvcentre/en/